Cepheid EVP Kerry Flom Sells 2,812 Shares (CPHD)
Cepheid (NASDAQ:CPHD) EVP Kerry Flom sold 2,812 shares of the company’s stock on the open market in a transaction dated Monday, July 14th. The stock was sold at an average price of $49.72, for a total transaction of $139,812.64. Following the completion of the transaction, the executive vice president now directly owns 989 shares in the company, valued at approximately $49,173. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Cepheid (NASDAQ:CPHD) traded down 4.00% during mid-day trading on Tuesday, hitting $47.95. 525,506 shares of the company’s stock traded hands. Cepheid has a 52-week low of $30.95 and a 52-week high of $55.89. The stock has a 50-day moving average of $46.80 and a 200-day moving average of $48.06. The company’s market cap is $3.343 billion.
Several analysts have recently commented on the stock. Analysts at Cowen and Company reiterated an “outperform” rating on shares of Cepheid in a research note on Thursday, July 10th. They now have a $58.00 price target on the stock, down previously from $62.00. Separately, analysts at Wells Fargo & Co. initiated coverage on shares of Cepheid in a research note on Wednesday, July 9th. They set an “outperform” rating on the stock. Finally, analysts at Craig Hallum upgraded shares of Cepheid from a “sell” rating to a “hold” rating in a research note on Monday, June 9th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $51.71.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.